Boston, MA 06/24/2013 (wallstreetpr) – The share prices of Geron Corporation (NASDAQ:GERN) has advanced by 9.01 percent to close at $1.21 per share for the end of last trading session on Friday. The openings price of the share is $1.12per share. The shares of the company had been trading range of $1.11 to $1.23 per share during the day. The shares of the company had thereby adjusted to 52 week high price level of $2.99 per share and the 52 week low price level of the company is at $0.91 per share.
The company is a biopharmaceutical company developing therapies for cancer. The company has two product candidates in clinical development, imetelstat and GRN 1005. Imetelstat a telomerase inhibitors that is being evaluated in for Phase 2 clinical trials: metastatic breast cancer, advanced non-smell lung cancer, essential thrombocythemia and multiple myeloma.
Heading into Q2, a total of 5 of the hedge funds, for track were long in this stock a change of -29 percent from the previous quarter. With hedge funds’ positions which undergoing their usual flow and ebb, that exists a few notables hedge fund managers who were boosting their holdings considerably.
GERN has experienced declining sentiment from the entirely of the hedge funds, it’s safe to say that there exists a select few hedgies and they are decided to sell off their positions entirely from last quarter. At the top of the heap, Steven Cohen’s SAC Capital Advisors sold off the largest investment of the entire hedgies key on, totaling an estimated $0 million in stock.
The GERN shares of had thereby been trading in volumes with nearly 4.18 million trades being executed on Friday against an average volume of 787,837 shares per day. The company presently holds outstanding shares of 130.43 million in the market with an institutional ownership of 33 percent of its holdings.
